| abstract |
Disclosed are histamine H 3 antagonists of the formula (I) whereinnR 1 is benzimidazolone derivative, M 1 and M 2 arenoptionally substituted carbon or nitrogen, R 2 includes optionallynsubstituted aryl or heteroaryl, and the remaining variables are as defined innthe specification. Also disclosed are pharmaceutical compositions comprisingnthe compounds of formula (I). Also disclosed are methods of treating variousndiseases or conditions, such as, for example, allergy, allergy-induced airwaynresponses, and congestion (e.g., nasal congestion) using the compounds of Formulan(I). Also disclosed are methods of treating various diseases or conditions,nsuch as, for example, allergy, allergy-induced airway responses, and congestionn(e.g., nasal congestion) using the compounds of formula (I) in combination withna H 1 receptor antagonist. |